

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

At scoping, 1 stakeholder expressed concerns regarding the use of the severity modifier which categorises patients by age when determining the absolute and to a lesser extent the proportionate shortfall. For the severity modifier calculation, the average age of the trial population was used. The committee did not consider that any particular age group was disadvantaged using the average age from the trial.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not relevant.

7. Have the committee's considerations of equality issues been described in the draft guidance consultation document, and, if so, where?
Not applicable.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 18 September 2023